Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine Mindmed Inc (NQ: MNMD )

8.170 -0.090 (-1.09%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine Mindmed Inc

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
BioMedNewsBreaks – Mind Medicine (‘MindMed’) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) Engages with FDA for Development of the ‘MSMS’
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Psilera's DMT-Derived Drug Sees Positive Results in Pre-Clinical Study
Psilera is a Florida-based biotechnology company focused on developing drugs to treat mental disorders using non-hallucinogenic derivatives from psychedelic compounds. The... 
Via Benzinga
Topics Derivatives
Exposures Derivatives
FDA Shows Support For Development Of MindMed's Session Monitoring System
Psychedelic-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) recently met with the US Food and Drug Administration (FDA) Center for Devices and... 
Via Benzinga
Exposures Product Safety
This Company Is Making Synthetic Psychedelics With a Goal To Combat Mental Illness
Photo by Michael Longmire on... 
Via Benzinga
MNMD Stock Pops Higher After MindMed Unveils ‘Psychedelic’ Data
MNMD stock is up today after MindMed reported positive findings on the interactions between psilocybin and an antidepressant. 
Via InvestorPlace
Antidepressants Can Be Used During Psilocybin Treatment, A New MindMed & Liechti Lab Study Finds
Psychedelics-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced the publication of its first data on the interaction of a selective... 
Via Benzinga
Psychedelic Drug Stocks Continued To Decline Last Week
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November. 
Via Talk Markets
3 Psychedelic Stocks for Potential Out-of-This-World Gains
Psychedelic drugs could be a major game-changer when it comes to treating mental illness. All as psilocybin, LSD, and MDMA show progress. 
Via InvestorPlace
Intranasal Ketamine Garnering A lot of Attention as an Effective Treatment For Depression
Palm Beach, FL –November 23, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic is expected to have a significant positive impact on the growth of the global antidepressant market.... 
Via FinancialNewsMedia
Exposures COVID-19
MindMed Q3 Earnings: Big Improvement, Kicks Off Sleep & Cognitive Study With Dose Low-Dose LSD
MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a biotech company developing psychedelic-inspired therapies, announced its financial results late Monday for the third quarter... 
Via Benzinga
Cannabis Movers & Shakers: Mind Medicine, Avant Brands, Delic, Agrify, Ascend Wellness, Pure Beauty
Mind Medicine Appoints Maria A. Oquendo To Scientific Advisory Board Psychedelic-focused biotech company Mind Medicine Inc. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others
Compass Pathways reported 
Via Talk Markets
Behind the Wall: Psychedelics Have “Absolutely Transformational” Potential
Is now the time to invest in psychedelic stocks? Dustin Robinson, founder of venture capital firm Iter Investments, says yes and explains why. 
Via InvestorPlace
Compass Pathways Goes On Bad Trip, Despite 'Positive' Results From Psilocybin Trial
Shares plunged, despite a psilocybin-based drug reducing depression in a trial. 
Via Investor's Business Daily
This Could Be The Next Multi-Billion AI Breakthrough
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 5, 2021 – There’s a massive announcement set to take place later this year, and it could change the $12 trillion... 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Compass Pathways 2.0: A New Rally In Psychedelic Stocks?
Compass Pathways' IPO sparked a sector-wide rally in 2020. Now CMPS is on the move again. Is history about to repeat? 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Psychedelics Offer Hope for Mental Disorders, Addiction
Via Investor Brand Network
How This Company Is Using Psychedelic Medicines and Therapies to Treat Addiction and Mental Illness
Courtesy of: MindMed The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored c... 
Via Benzinga
Magic Mushrooms and Ecstasy: New Treatment For Autism Spectrum Disorders?
Much like cannabis, psychedelics are catch... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Psyched: MindMed's MDMA Program For Autism, Small Pharma's New Patent, NovaMentis' Orphan Drug Designation
The Week In Psychedelics: 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Developments with Ketamine Psychotherapy Are Driving A Medical Revolution For Treating Mental Health Issues
Palm Beach, FL –October 28, 2021 – FinancialNewsMedia.com News Commentary – Psychedelic drugs such as psilocybin, LSD and MDMA have tremendous medical and commercial future potential… and for ketamine,... 
Via FinancialNewsMedia
Topics Death Law Enforcement
Exposures Death Legal
Biotech Companies Are Embracing the Growing Psychedelic Drug Market To Confront a Global Increase in Depression and Anxiety
Image by 3D Animation Production Company from Pixabay The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team... 
Via Benzinga
North America Continues Leading The Way In Psychedelic Wellness
Palm Beach, FL –October 26, 2021 – FinancialNewsMedia.com News Commentary – The global psychedelic drugs market remains at an early stage in its life cycle, with most companies currently developing... 
Via FinancialNewsMedia
Phase 2 Trial On Ayahuasca's Active Ingredient Puts Small Pharma On Track To Winning The Psychedelics Race
Small Pharma Inc. (OTCQB:DMTTF) (TSXV: 
Via Benzinga
Two Trillion-Dollar Industries Being Transformed By Tech
FN Media Group Presents Oilprice.com Market Commentary London – October 20, 2021 – Big money is pouring into two disruptive segments in two of the world’s biggest industries – healthcare and energy.... 
Via FinancialNewsMedia
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
The Week In Psychedelics 
Via Benzinga
Forget The Hype: The Psychedelic Stocks Sector Went Down In The Third Quarter Of 2021
Despite the prevailing hype, the psychedelic sector went down considerably last quarter (July through September) and has gone down even further so far this month. 
Via Talk Markets
Rising Acceptance For Treating Mental Disorders is Fueling Strong Growth in Psychedelic Drugs Market
Palm Beach, FL –October 14, 2021 – FinancialNewsMedia.com News Commentary – Mental disorders are an urgent health crisis worldwide, especially exacerbated by COVID-19. As per a study by Harvard, the... 
Via FinancialNewsMedia
Exposures COVID-19
Psychedelic Stocks: Financial Strength, Growth Potential, Compelling Valuations
Blue-chip stocks: grossly inflated valuations and loaded with debt. Psychedelic stocks: lean valuations and loaded with cash. A very attractive option in uncertain markets. 
Via Talk Markets
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.